文献速递关节外科

全膝关节置换术后阿司匹林与强效静脉血栓栓塞预防比较:阿司匹林减少术后疼痛和并发症

Aspirin Versus Potent Venous Thromboembolism Chemoprophylaxis in Total Knee Arthroplasty: Reduced Postoperative Pain and Complications With Aspirin Use.
PubMed 文献 · J Arthroplasty · 2026-04-01

单中心回顾性研究纳入2016至2023年14,216例因骨关节炎行初次全膝关节置换术的患者,比较阿司匹林与强效抗凝药对术后疼痛和早期结局的影响。强效抗凝组90天门诊及总阿片类药物用量更高、住院时间更长、180天内手法松解和90天再入院风险更高,而静脉血栓栓塞等事件无差异。结论提示在医学适宜时阿司匹林应作为静脉血栓栓塞预防的首选。

要点

  • 强效抗凝组90天门诊阿片用量较阿司匹林组增加285.0 MMEs(P<0.001)。
  • 强效抗凝组住院时间延长12.1小时,180天手法松解风险增加(OR 1.45)。
  • 两组静脉血栓栓塞、心肌梗死、再手术和伤口引流无差异(P>0.36)。

核心结论

  • 全膝关节置换术后使用强效抗凝药预防静脉血栓栓塞的患者,术后90天疼痛更重、阿片需求更高、住院时间更长且手法松解风险增加。
  • 在医学适宜时,阿司匹林应优先用于静脉血栓栓塞预防以降低术后疼痛风险。

研究设计与样本

  • 单中心回顾性研究,纳入2016至2023年因骨关节炎行初次全膝关节置换术的14,216例患者。
  • 术后静脉血栓栓塞预防方案包括阿司匹林9,076例、强效抗凝药4,506例和长期强效抗凝药661例。
  • 采用多变量回归模型控制相关临床变量后评估结局。

主要发现

  • 与阿司匹林组相比,强效抗凝组90天门诊阿片用量调整后平均差异为+285.0 MMEs(P<0.001),总阿片用量差异为+295.6 MMEs(P<0.001)。
  • 长期强效抗凝组90天门诊和总阿片用量分别增加127.7 MMEs(P=0.002)和127.3 MMEs(P=0.002)。
  • 强效抗凝组住院阿片用量增加10.5 MMEs(P<0.001),住院时间延长12.1小时(P<0.001),长期强效抗凝组住院时间延长5.6小时(P<0.001)。
  • 强效抗凝组180天内手法松解风险增加(OR 1.45;P=0.0003),90天再入院风险增加(OR 1.31;P=0.004)。
  • 静脉血栓栓塞、心肌梗死、再手术和伤口引流在组间无差异(P>0.36)。

临床怎么用

  • 对于医学上适宜的全膝关节置换术后患者,可优先选择阿司匹林进行静脉血栓栓塞预防,以减少术后疼痛和阿片需求。
  • 使用强效抗凝药时应关注术后疼痛管理、阿片用量、住院时间及手法松解风险。

局限性

  • 研究为单中心回顾性设计,可能存在选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal postoperative venous thromboembolism chemoprophylaxis (VTEC) to balance venous thromboembolism (VTE) reduction with pain management, wound complications, and functional outcomes remains controversial. This study compared postoperative pain and early outcomes in patients undergoing total knee arthroplasty (TKA) who received aspirin versus potent anticoagulation (AC) regimens. METHODS: We identified 14,216 primary TKAs for osteoarthritis performed between 2016 and 2023 at a single institution. Postoperative VTEC regimens included aspirin in 9,076 patients, potent AC (i.e., apixaban, rivaroxaban, warfarin, heparin, and enoxaparin) in 4,506, and chronic potent AC in 661. Outcomes included in-hospital opioid consumption (morphine milligram equivalents [MMEs]), lengths of stay (LOS), 90-day outpatient opioids, 180-day manipulations under anesthesia (MUA), and 90-day complications. Outcomes were assessed with multivariable regression models controlling for relevant clinical variables. RESULTS: Compared to the aspirin group, 90-day outpatient and total opioid use was higher in the AC group (adjusted mean difference: +285.0 MMEs; P < 0.001 and +295.6 MMEs; P < 0.001, respectively) and chronic AC group (+127.7 MMEs; P = 0.002 and +127.3 MMEs; P = 0.002). In-hospital opioid use was higher in the AC group (+10.5 MMEs; P < 0.001). Lengths of stay were longer for AC (+12.1 hours; P < 0.001) and chronic AC groups (+5.6 hours; P < 0.001). The AC group had higher odds of MUA within 180 days (odds ratio: 1.45; P = 0.0003) and 90-day readmission (1.31; P = 0.004). No differences were observed for VTE, myocardial infarction, reoperation, or wound drainage (P > 0.36). CONCLUSIONS: The TKA patients treated with potent AC for VTE prophylaxis versus aspirin experienced more postoperative pain in the first 90 days, higher opioid requirements, increased LOS, and increased risk of MUA. Aspirin should be favored for VTEC to reduce the risk of postoperative pain in TKA patients when medically appropriate.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Gonzalez AG, Anatone AJ, Logsdail ES, et al. Aspirin Versus Potent Venous Thromboembolism Chemoprophylaxis in Total Knee Arthroplasty: Reduced Postoperative Pain and Complications With Aspirin Use. J Arthroplasty. 2026. PMID: 41963221. doi:10.1016/j.arth.2026.03.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。